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Abstract
Background: Peste des petits ruminants (PPR) is a highly contagious infectious disease of goats, sheep and small wild
ruminant species with high morbidity and mortality rates. The Peste des petits ruminants virus (PPRV) expresses
a hemagglutinin (H) glycoprotein on its outer envelope that is crucial for viral attachment to host cells and represents a key
antigen for inducing the host immune response.
Methodology/Principal Findings: To determine whether H can be exploited to generate an effective PPRV vaccine,
a replication-competent recombinant canine adenovirus type-2 (CAV-2) expressing the H gene of PPRV (China/Tibet strain)
was constructed by the in vitro ligation method. The H expression cassette, including the human cytomegalovirus (hCMV)
promoter/enhancer and the BGH early mRNA polyadenylation signal, was inserted into the SspI site of the E3 region, which
is not essential for proliferation of CAV-2. Infectious recombinant rCAV-2-PPRV-H virus was generated in transfected MDCK
cells and used to immunize goats. All vaccinated animals produced antibodies upon primary injection that were effective in
neutralizing PPRV in vitro. Higher antibody titer was obtained following booster inoculation, and the antibody was
detectable in goats for at least seven months. No serious recombinant virus-related adverse effect was observed in
immunized animals and no adenovirus could be isolated from the urine or feces of vaccinated animals. Results showed that
the recombinant virus was safe and could stimulate a long-lasting immune response in goats.
Conclusions/Significance: This strategy not only provides an effective PPR vaccine candidate for goats but may be
a valuable mean by which to differentiate infected from vaccinated animals (the so-called DIVA approach).
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Introduction
Peste des petits ruminants (PPR) is an acute and highly
contagious disease of small ruminants, particularly affecting goats
and sheep. Disease onset is characterized by fever and somno-
lence; within a few days, mucosal erosions occur, accompanied by
oral and ocular discharge, diarrhea, and symptoms of pneumonia.
The disease may resolve after a prolonged convalescent period,
but more frequently leads to death [1]. PPR was first described in
1942 in Co ˆte d’Ivoire as a fatal disease of small ruminants that
resembled rinderpest of cattle. Since then, PPR has spread
throughout west and sub-Saharan Africa, the Middle East, the
Indian subcontinent, Turkey, some countries in Central Asia, and
China [2–9]. Currently, PPR is responsible for significant
economic losses in goats and sheep productivity in the endemic
regions.
PPR is caused by Peste des petits ruminant virus (PPRV),
a member of the genus Morbillivirus, family Paramyxoviridae
[10,11]. PPRV, like other morbilliviruses, is an enveloped,
nonsegmented negative-strand RNA virus. PPRV expresses two
external glycoproteins, fusion (F) and hemagglutinin (H), which
mediate infectivity. The H protein binds to its cognate receptor on
the host cell during the first step of the viral infection process; as
such, it acts as a major antigen that stimulates a protective immune
response in the host [12–14].
PPR has been controlled for many years by the use of
a rinderpest virus (RPV) tissue culture-adapted vaccine [15].
However, the remarkable success of the global rinderpest
eradication program has led to the RPV vaccine being banned
from use within rinderpest-free zones; the fear is used in any
species, including the PPRV-susceptible small ruminants, would
hinder the establishment of the serologically negative population.
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.In response to this ban, a homologous PPR vaccine was
produced by passaging the Nigeria 75/1 strain of PPRV 63 times
in Vero cells [16], and is now being introduced into some PPR-
endemic regions. While this vaccine produces a sufficient PPRV
neutralizing response, it is not optimal for two main reasons. First,
PPRV, like all members of the family Paramyxoviridae, is very
heat sensitive and its endemic areas are nearly all in hot climates.
Second, the live attenuated PPRV vaccine generates a broad
range of immune responses to viral proteins, making it difficult to
serologically distinguish vaccinated animals from those naturally
infected. Ultimately, sero-epidemiosurveilance of the disease is
impossible in endemic areas where a vaccination program has
been or is being implemented [17]. Thus, the live attenuated
tissue-culture approach needs to be replaced by a vaccine strategy
that will facilitate differentiating infected from vaccinated animals,
the so-called ‘‘DIVA’’ vaccines [18].
Over the past decade, adenoviruses have emerged as particu-
larly promising vaccine delivery vehicles. They are double-
stranded DNA viruses with high genetic stability, exhibiting no
mutations or insertion/deletions after multiple rounds of replica-
tion in vitro. Furthermore, they do not integrate into the genome of
the infected host, and consequently present less of a safety concern
for gene delivery since there is little risk of insertional mutagenesis
and expression of potentially toxic or deleterious gene products
[19–21]. Due to their nonenveloped structure, adenoviruses are
physically stable and can withstand lyophilization, suggesting
a convenient means for storage, transport, and vaccine formula-
tion that is amenable to global distribution.
Two serotypes of canine adenovirus (CAV) have been isolated.
Both CAV-1 and CAV-2 are associated with mild upper
respiratory tract infections in dogs, and effective and safe live-
modified vaccines are available for routine vaccination of dogs
against both. The structure, replication, and transcription of CAV-
2 are very well-characterized and it has been more extensively
utilized for vector development [22]. When foreign genes are
inserted into the non-essential E3 region of CAV-2, replication of
the recombinant virus is not impacted, resulting in high virus titers
and high-level gene expression [23,24]. Here, we describe the
development of a recombinant canine adenovirus type-2 delivery
vector expressing the H gene of PPRV and its utility as a vaccine
in experimental goats.
Results
Identification of Recombinant virus CAV-2-H
We successfully generated a recombinant virus rCAV-2-PPRV-
H expressing the PPRV H protein. The H gene expression cassette
was subcloned into the E3 region of the pPolyII-CAV-2 plasmid,
generating a recombinant genome pPolyII-CAV-DE3-H (Fig. 1).
The identification of the plasmid pVAX-H, pVAXDE3-H and
pPolyII-CAV-DE3-H by restriction endonuclease digestion con-
firmed that the H gene and its expression cassette were included in
the recombinant virus (data not shown). Eleven days after
transfection, typical CPE (grape-cluster-like cells) was observed
under a microscope. Adenovirus-like particles were observed
under the electron microscope. The growth characteristics of the
recombinant virus were similar to that of the canine adenovirus
vaccine strain YCA18. The TCID50 of the rCAV-2-PPRV-H virus
was assayed and calculated to be 10
7.8/mL. This virus hemagglu-
tinates human red blood cells and has an HA titer of 1:2
9, which is
similar to the titer of the canine adenovirus vaccine strain YCA18.
The genome of rCAV-2-PPRV-H was analyzed for genetic
stability by restriction enzyme analysis and found to retain the
correct genome structure at the 30th serial passage (data not
shown).
Western Blotting
Recombinant adenovirus-infected MDCK cell lysates were
examined by Western blotting and compared with results from the
negative control canine adenovirus vaccine strain YCA18.
Immunoreactivity of H protein (approximately 70 kD) was found
in recombinant adenovirus-infected cell lysates, but not in vaccine
strain YCA18 (Fig. 2), indicating that the expressed H protein
retained its antigenic reactivity.
At passage 30, the results of RT-PCR detection of H protein of
PPRV and Western blotting analysis of H protein expressed by
recombinant virus were the same (data not shown). All results
indicated that the recombinant virus was stable enough to
maintain its genetic integrity.
Immunofluorescence
The cellular localization of the H protein expressed by the
recombinant adenovirus was investigated immunologically using
fixed MDCK cells. H protein expression was readily detected on
the surface of MDCK cells infected with CAV-2-PPRV-H (Fig. 3).
Antibody Assays
In test goats (The designs of the animal experiments are shown
in Table 1), neutralizing antibody titers against PPRV at week 3
after the primary vaccination ranged from 1:32–1:64 with rCAV-
2-PPRV-H, 1:64–1:128 with the attenuated PPR vaccine, and
,1:2 with CAV-2 injection. At weeks 5–6 (two to three weeks after
the booster injection) goats who received rCAV-2-PPRV-H
exhibited the highest neutralizing titers against H protein. At
thirty weeks after primary injection, at the end of the trial, titers
were still above the protective level of 1:10, which indicated that
the antibody may persist for a longer time. Comparatively,
neutralizing antibody titers induced by the attenuated PPR
vaccine reached higher levels than those induced by rCAV-2-
PPRV-H from week 2 after the primary vaccination and onward
(Table 2).
The HI antibodies against CAV-2 continually increased from
week 2 after vaccination, which corresponded with the appearance
of PPRV neutralizing antibody; however, the increase of the
PPRV neutralizing antibody was more gradual. The highest HI
titer of the goat serum was 1:1024, which dropped to 1:64 by week
30 (Table 3).
Lymphocyte Proliferation Responses
All the test groups of goats produced robust lymphoproliferative
responses, as compared to the PBS control (P,0.05); however,
there was no significant difference in the responses between the
goats immunized with attenuated PPRV vaccine, rCAV-2-PPRV-
H, or CAV-2 (P.0.05) (Table 4).
Discussion
Attenuated canine adenovirus type 2 has proved to be an
effective vaccine strain used for prevention of canine hepatitis and
infectious laryngotrachitis. Although canine adenovirus is a natural
pathogen of dogs, it replicates efficiently in goats following
inoculation by various routes, including subcutaneous and in-
tramuscular (in our preliminary experiment). Attenuated CAV-2
has also been shown to be safe in other animals, including cats,
foxes and swine [25–27]. As with human adenoviruses, a CAV-2
expression vector with a deleted E3 has some advantageous
features for gene delivery applications: it replicates efficiently to
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recombinant proteins in most mammalian cell lines and tissues,
and accurately expresses and modifies recombinant proteins.
Another important advantage of CAV-2 is the fact that as a natural
canine pathogen there are no pre-existing, maternally-derived
antibodies in livestock, which could otherwise interfere with
vaccine efficacy in young and growing goats.
As a feasibility study, evaluation of the safety of the vaccine is an
important concern. Regardless of efficacy, a recombinant virus
must cause minimal to no adverse effects in experimental animals.
The rCAV-2-PPRV-H could not be isolated from the urine or
feces of vaccinated goats, up to the end of the monitoring period
on day 35 post-inoculation. This finding further indicated that the
recombinant virus could not be shed through urine and feces of
immunized goats to contaminate the environment during this
period. In another experiment (data not shown), we checked the
horizontal infection rates of the recombinant virus by evaluating
goats in close contact (living in the same yards) with vaccinated
goats; antibodies against CAV-2 or PPRV were not detected in the
in-contact control animals, further ruling out the possibility of
rCAV-2-PPRV-H shedding from experimental animals with the
recombinant virus.
In order to analyze which immunization route could be better
and more efficient to enhance high level neutralizing antibody, we
also investigated different routes of administration for the
recombinant virus. However, the only effective route of in-
oculation for eliciting neutralizing antibodies against PPRV in
goats was intramuscular injection. The oral inoculation and
intranasal administration did not produce any antibodies against
either adenovirus or PPRV (data not shown), indicating that no
effective immune reaction can be elicited by these two routes. This
suggested that goats could not be naturally infected with CAV-2,
especially since there was no antibody against CAV-2 in goats
before administration. Avoiding interference of pre-existing
antibodies is an important requirement for successful recombinant
vaccine; the fact that there is no chance of pre-existing antibody
interference to CAV-2 in goats enhances the potential of this
adenovirus vaccine to stimulate a strong and efficient immune
response.
The hemagglutinin protein of PPRV has been shown to play
a crucial role in stimulating antibody responses against PPR
infection [28]. According to standards of OIE, a VNT of 10 is the
minimum value for quality control and efficacy evaluation for the
PPR-like attenuated vaccine, Nig/75/1 [29]. In order to enhance
the level of immune responses of rCAV-2-PPRV-H in our
experimental goats, immunizations with rCAV-2-PPRV-H were
carried out twice with the same dose at 21-day intervals. The titers
of neutralizing antibody against PPRV induced by rCAV-2-
PPRV-H were significantly enhanced after booster of rCAV-2-
PPRV-H. A single immunization of rCAV-2-PPRV-H induced
the antibody against PPRV up to 1:32-1:64 within three weeks.
After the booster, a titer of 1:64–1:128 was achieved, which
surpassed the minimum required level for PPRV by a considerable
margin.
Although the antibody response against PPRV has largely been
considered the most important factor in efficient protection, good
cellular immunity stimulated by a vaccine would also enhance this
efficiency and persistence, as well as induce more durable
immunity. Therefore, we also investigated the cell-mediated
immune response in goats by lymphocyte proliferation assay. Live
attenuated vaccines are known to be efficient in inducing long-
lasting immunity via cellular and humoral immune responses
[30,31]. The data from the lymphocyte proliferation assay showed
that, as compared with the negative control, the three groups
immunized with attenuated PPRV, rCAV-2-PPRV-H, and CAV-
2 stimulated similar high cellular immune responses; in addition,
the cell-mediated immunity efficacies between the attenuated
PPRV group and rCAV-2-PPRV-H group were nearly identical.
Even if the VNA titer of the recombinant virus vaccinated animal
is undetectable, the animal may still be protected against PPRV
challenge [32]. This further demonstrated that cell-mediated
immunity plays a very important role in PPR vaccines.
In summary, a novel recombinant canine adenovirus expressing
the H protein of PPRV was constructed, and the recombinant
virus rCAV-2-PPRV-H expressed the H protein efficiently and
induced humoral and cellular immunity against PPRV in goats.
This adenovirus vector might be an attractive candidate DIVA
vaccine for preventing the disease associated with PPRV infection
and facilitating sero-epidemiosurveilance of PPR.
Materials and Methods
Cells, viruses, Genes and Plasmids
Madin-Darby canine kidney (MDCK) cells (American Type
Culture Collection (ATCC), CCL-34) were cultured in Dulbecco’s
Modified Essential Medium (DMEM; Invitrogen, USA) contain-
ing 10% (v/v) heat-inactivated fetal bovine serum (FBS; Gibco,
USA), penicillin (100 U/mL) and streptomycin (100 mg/mL).
Eighty percent confluent cells were used for transfection with the
recombinant genome and fully confluent cells were infected with
the recombinant virus for propagation and production. Vero cells
(ATTC, CCL-81) were cultured in Minimum Essential Medium
(MEM; Gibco) containing 10% FBS. Live attenuated PPRV
vaccine strain Nigeria/75/1 (Nig/75/1) was obtained from the
China Institute of Veterinary Drug Control. CAV-2 strain YCA
18 was isolated by Xia et al. [33]. A complete PPRV cDNA
derived from a PCR product of PPRV strain China/Tibet/Geg/
Figure 1. Schematic diagram showing the construction strategy of the recombinant virus rCAV-2-PPRV-H. Cassette expression is under
the control of the CMV promoter.
doi:10.1371/journal.pone.0037170.g001
Figure 2. Western blotting analysis of the PPRV H produced in
MDCK cells infected with rCAV-2-PPRV-H or CAV-2. Lanes: 1, MV
Marker; 2, MDCK cells infected with rCAV-2-PPRV-H; 3, MDCK cells
infected with CAV-2.
doi:10.1371/journal.pone.0037170.g002
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the China Animal Health and Epidemiology Center. Plasmid
pPOLYII-CAV-2, containing the whole genome of canine
adenovirus type-2, was constructed and described by Zhang et
al. [34]; it was chosen for use here based on its features as an
infectious plasmid that can produce canine adenovirus particles
after transfection of MDCK cells.
The Construction of pPolyII-CAV-DE3-H
The open reading frame (ORF) of the PPRV glycoprotein gene
H was amplified by RT-PCR using the following primer pair,
which introduced KpnI and XhoI restriction enzyme sites at the
respective 59-termini (underlined): forward primer H1, 59-
CCGGTACCATGGCCGCACAAAGGGAAAG-39 (the com-
plete Kozak sequence in bold); reverse primer H2, 59-
GCGCTCGAGTCAGACTGGATTACATGTTACCTC-39.
The PCR product of the H gene was subcloned into the pMD18-T
vector (TaKaRa, China), and the resultantpMD18-T-H vector
was sequenced by the UN Corporation of Shanghai, China. The
4.8 kb KpnI fragment containing the E3 region from pPolyII-
CAV-2 was first cloned into pVAX1 (Invitrogen) to generate
pVAX-DE3. The H sequence was released with KpnI and XhoI
from pMD18-T-H and cloned into the KpnI/XhoI sites of pVAX1
to generate pVAX-H. The MluI/HaeII fragment of pVAX-H,
containing the H cDNA expression cassette driven by the
cytomegalovirus (CMV) immediate early promoter with BGH
polyadenylation signals at the other end of the gene, was blunted
using a DNA blunting kit (TaKaRa) and directionally cloned into
the SspI site of pVAX-DE3, forming the pVAXDE3-H vector. The
NruI and SalI double digest pVAXDE3-H fragment containing the
H expression cassette flanked with residual E3 sequences was
cloned back into pPolyII-CAV-2 by replacing the fragment
between the NruI and SalI sites, forming the final pPolyII-CAV-
DE3-H plasmid (Fig. 1). The recombinant genome was purified for
use in transfection. The preparation, cloning and identification of
genes and recombinant plasmids were performed according to
standard methods [35].
Transfection of the Recombinant Genome in MDCK Cells
and Production of Recombinant virus
MDCK cells were transfected with recombinant genome
pPolyII-CAV-DE3-H using Lipofectamine2000
TM (Invitrogen),
according to the manufacturer’s protocol. Briefly, MDCK cells
(2.5610
5 cells/well) were cultured in six-well tissue culture plates
(Nunc, USA). At approximately 70–80% confluence, supernatant
medium was removed and cells were washed with OPTI-MEM
(Gibco). Four micrograms of purified linearized recombinant virus
genome were dissolved in 250 mL OPTI-MEM, and then mixed
with 10 mL Lipofectamine2000
TM dispersed in 250 mL OPTI-
MEM and incubated at room temperature for 20 min. The
transfection mix was then spread over the 80% confluent MDCK
cells and incubated for six hours, when it was replaced by 2 mL
complete DMEM (5% FBS). Transfected cells were incubated at
37uC and blind-passaged until cytopathic effects (CPE) appeared,
when samples of cell lysates were collected for electron
microscopic examination using negative staining with potassium
phosphotungstate.
Western Blotting
The supernatant of the recombinant virus cell culture lysates
was separated on 15% SDS-PAGE gels and the proteins were
transferred onto a nitrocellulose membrane (Bio-Rad, USA). The
proteins were probed with goat anti-PPRV antiserum (1:200) and
horseradish peroxidase-labeled donkey anti-goat IgG antibody
(1:5000; Sigma, USA), according to the protocols described
elsewhere [36].
Immunofluorescence Analysis
To analyze expression of H protein on the surface of cells,
MDCK cells were infected with CAV-2, rCAV-2-H, at a multiple
of infection (m.o.i.) of 1 for 48 h. Afterwards, infected cells were
fixed with 4% paraformaldehyde for 20 min at room temperature
and treated with 0.1% Triton-X100. After washing three times
with PBS, cells were incubated with goat anti-PPRV antiserum
(1:200), followed by Alexa FluorH 488-conjugated donkey anti-
Figure 3. Fluorescence microscopy analysis of PPRV H protein in recombinant virus-infected MDCK cells. MDCK cells were infected
with rCAV-2-PPRV-H (A) or CAV-2 (B) at 1 m.o.i. Negative controls were untransfected cells (C). After 48 h, the infected cells were detected with goat
anti-PPRV antiserum, followed by Alexa FluorH 488-conjugated donkey anti-goat IgG and observed under fluorescence microscope.
doi:10.1371/journal.pone.0037170.g003
Table 1. Experimental designs of the animal studies.
Group Vaccine Route Dosage Dose
A-1(n=35) rCAV-2-PPRV-H IM 10
7.8 TCID50 2 doses, 3 weeks
interval
A-2(n=21) rCAV-2-PPRV-H IM 10
7.8 TCID50 2 doses, 3 weeks
interval
B(n=3) Attenuated
PPRV
IM 10
7.8 TCID50 2 doses, 3 weeks
interval
C(n=3) CAV-2 IM 10
8 TCID50 2 doses, 3 weeks
interval
IM stands for intramuscular.
doi:10.1371/journal.pone.0037170.t001
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determined using a fluorescence microscope (BX51FL; Olympus,
Japan).
Animal Inoculation
A total of sixty-two outbred goats (6–24 months of age) were
used for animal study. All goats had no detectable levels (titers
,1:2) of PPRV neutralizing antibodies or CAV hemagglutination-
inhibition antibodies. To investigate the immunogenicity of rCAV-
2-PPRV-H in goats, thirty-five goats were randomly assigned to
group A-1 and received an intramuscular injection of 10
7.8
TCID50 rCAV-2-PPRV-H. Twenty-one goats in group A-2 were
used to investigate the PPRV VNA duration in goats immunized
with rCAV-2-PPRV-H. Three goats were randomly assigned to
group B and were intramuscularly inoculated with 10
7.8 TCID50
attenuated PPRV vaccine. The remaining three goats made up
group C (the negative control group) and received intramuscular
injection of 10
8 TCID50 CAV-2. All three groups received booster
injection of the original dosage at three weeks after primary
immunization. Every 3 weeks after primary immunization,
animals were bled from the jugular vein. Sera were separated
and stored at -20uC until analyzed.
The animal experiments were conducted with prior approval
from the Animal Welfare and Ethics Committee of the Veterinary
Institute at the Academy of Military Medical Sciences, China
under the permit number (SCXK-2002-018). All manipulation of
the goats satisfied the requirements of the Regulations of
Experimental Animal Administration of PR China.
For one month after vaccination, all goats were monitored daily
for clinical signs. Urine and feces samples were collected from
goats inoculated with rCAV-2-PPRV-H and CAV-2 every two
days for the first month. The samples were suspended in DMEM
(5% FBS, 200 U/mL penicillin and 200 mg/mL streptomycin)
and centrifuged at low speed to remove particulates. Supernatants
were collected and used to inoculate MDCK cell monolayers,
according to the previously described protocol [37].
Canine Adenovirus Hemagglutination Inhibition (HI)
Canine adenovirus type-2 HI antibody titer was assayed
according to the published protocol [38]. Briefly, goats from
different groups were vaccinated with attenuated PPRV vaccine,
rCAV-2-PPRV-H, or CAV-2 and the serum samples were
collected at weeks 0-30 following the primary vaccination. Serial
2-fold dilutions of sera were mixed with 25 mL CAV-2, titer 4 HA
units, with PBS (0.01 M, pH 7.2) as the control, and incubated at
37uC for 30 min. Then, 25 mL 1% human group O red blood cells
suspended in PBS (pH 7.2) were added to each well and incubated
at 37uC for 1 h. Titers were determined as the highest dilution
showing at least partial agglutination.
Virus Neutralization Test (VNT)
VNT was performed according to the recommendations from
the World Organization for Animal Health (formerly, the Office
International des Epizooties (OIE)). Briefly, the vaccine strain of
PPRV (Nig 75/1) was grown in Vero cells. Aliquots of virus (100
TCID50) were incubated at 37uC for one hour with serial dilutions
of the test or control sera (heat inactivated at 56uC for 30 min) and
then were added to Vero cells growing in a flat-bottom 96-well
tissue culture plate. Cells were observed microscopically for CPE
starting at day 3 post-infection. The CPE recorded at day 5 was
used for the calculation of PPRV virus neutralization (VNA) titers.
Virus neutralization titer was defined as the highest serum dilution
that inhibited CPE by at least 50%.
Lymphocyte Proliferation Assay
Individual goats from experimental groups were bled from the
jugular vein at week 3 after the booster injection. Peripheral blood
mononuclear cells (PBMCs) were prepared as previously described
Table 2. Neutralizing Antibody titers against PPRV in goats immunized with attenuated PPRV vaccine, rCAV-2-H and CAV-2.
Group Weeks post-primary vaccination
0 3 6 9 12 15 18 21 24 27 30
A-1
a ,1:2 1:32–1:64 1:64–1:128 1:64–1:128 - - - - - - -
A-2
b ,1:2 1:32–1:64 1:64–1:128 1:64–1:128 1:64–1:128 1:64–1:128 1:64–1:128 1:32–1:64 1:32–1:64 1:32–1:64 1:32–1:64
B
c ,1:2 1:64–1:128 1:128–1:256 1:128–1:256 1:128–1:256 1:128–1:256 1:64–1:128 1:64–1:128 1:64–1:128 1:64 1:64
C
d ,1:2 ,1:2 ,1:2 ,1:2 ,1:2 ,1:2 ,1:2 ,1:2 ,1:2 ,1:2 ,1:2
The level of serum PPRV-specific IgG in goats was determined by VNA, and the serum samples were collected at weeks 0–30 following the primary vaccination.
abP.0.05,
acP,0.05,
bcP,0.05.
doi:10.1371/journal.pone.0037170.t002
Table 3. HI antibody titers of CAV-2 in goats immunized with attenuated PPRV vaccine, rCAV-2-H and CAV-2.
Group Weeks post-primary vaccination
0 3 6 9 12 15 18 21 24 27 30
A-1 ,1:2 1:2
5–1:2
6 1:2
8–1:2
10 1:2
9–1:2
10 –––––––
A-2
a ,1:2 1:2
5–1:2
6 1:2
8–1:2
10 1:2
9–1:2
10 1:2
8–1:2
10 1:2
8–1:2
10 1:2
7–1:2
9 1:2
7–1:2
8 1:2
6–1:2
7 1:2
6–1:2
7 1:2
5–1:2
6
B
b ,1:2 ,1:2 ,1:2 ,1:2 ,1:2 ,1:2 ,1:2 ,1:2 ,1:2 ,1:2 ,1:2
C
c ,1:2 1:2
5–1:2
6 1:2
9–1:2
10 1:2
9–1:2
10 1:2
9–1:2
10 1:2
9–1:2
10 1:2
7–1:2
9 1:2
7–1:2
9 1:2
6–1:2
7 1:2
6–1:2
7 1:2
6
abP,0.05,
acP.0.05,
bcP,0.05.
doi:10.1371/journal.pone.0037170.t003
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6 cells/well) were plated in 96-well plates, in
triplicate, and were challenged with 5 mg/mL of concanavalin A
for 48 h at 37uCi n5 %C O 2. The proliferative response was
determined by MTS assays using the Cell Titer 96H aqueous one
solution cell proliferation kit (Promega) and following the
manufacturer’s instructions. Uninfected cells cultured in medium
alone were used as negative controls. The lymphocyte pro-
liferation rate was quantified by the stimulation index (SI), which
was calculated as the ratio of OD490 nm of stimulated cells to
OD490 nm of negative controls.
Statistical Analysis
All data were conducted by two-way analysis of variance
(ANOVA) and Student’s t-test, using SPSS v.13.0 software. A P-
value of less than 0.05 was considered statistically significant.
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